85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05041426 (ClinicalTrials.gov) | December 6, 2021 | 20/4/2021 | Letermovir for CMV Prevention After Lung Transplantation | An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis | Lung Transplant;CMV | Drug: Letermovir;Drug: Valganciclovir | Fernanda P Silveira, MD, MS | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | United States |